Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080198 | 0.92 | CTSL (0.46) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL4569994 | 0.91 | CTSS (0.51) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL17082042 | 0.91 | CTSS (0.51) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL22041814 | 0.89 | CTSB (0.48) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL2206561 | 0.87 | MEN1 (0.47) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL14638218 | 0.87 | MEN1 (0.43) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL14650130 | 0.87 | MEN1 (0.43) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL30922877 | 0.86 | CTSL (0.44) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL28412808 | 0.86 | JAK2 (0.44) | CTSSCTSLCTSBMEN1KMT2A | |
| SCHEMBL30923062 | 0.86 | CTSL (0.44) | CTSSCTSLCTSBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CTSS 3039/4885CTSL 3689/4885CTSB 2846/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CTSS 3039/4885CTSL 3689/4885CTSB 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.